Completed PHASE3 INTERVENTIONAL 2-arm NCT05226598

Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)

A Randomized, Double-Blind, Phase 3 Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy as First Line Treatment for Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)

Sponsor: Merck Sharp & Dohme LLC

Conditions Metastatic Non-Small Cell Lung Cancer

Interventions Carboplatin Cisplatin Nab-paclitaxel Paclitaxel Pembrolizumab Pembrolizumab/Vibostolimab Pemetrexed

Updated 25 times since 2022 Last updated: Jan 16, 2026 Started: Mar 24, 2022 Primary completion: Sep 24, 2024 Completion: Jan 9, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Metastatic Non-Small Cell Lung Cancer, this trial is completed. The trial is conducted by Merck Sharp & Dohme LLC and has accumulated 25 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

25 versions recorded

Feb 2026 — Present [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Dec 2025 — Feb 2026 [monthly]

Active Not Recruiting PHASE3
Sep 2025 — Dec 2025 [monthly]

Active Not Recruiting PHASE3
Mar 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE3
Dec 2024 — Mar 2025 [monthly]

Active Not Recruiting PHASE3

▶ Show 20 earlier versions

Sep 2024 — Dec 2024 [monthly]

Active Not Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE3
Jun 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE3
Feb 2024 — Jun 2024 [monthly]

Active Not Recruiting PHASE3
Jan 2024 — Feb 2024 [monthly]

Active Not Recruiting PHASE3
Jun 2023 — Jan 2024 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
May 2023 — Jun 2023 [monthly]

Recruiting PHASE3
Apr 2023 — May 2023 [monthly]

Recruiting PHASE3
Mar 2023 — Apr 2023 [monthly]

Recruiting PHASE3
Feb 2023 — Mar 2023 [monthly]

Recruiting PHASE3
Jan 2023 — Feb 2023 [monthly]

Recruiting PHASE3
Dec 2022 — Jan 2023 [monthly]

Recruiting PHASE3
Nov 2022 — Dec 2022 [monthly]

Recruiting PHASE3
Oct 2022 — Nov 2022 [monthly]

Recruiting PHASE3
Sep 2022 — Oct 2022 [monthly]

Recruiting PHASE3
Jul 2022 — Sep 2022 [monthly]

Recruiting PHASE3
Jun 2022 — Jul 2022 [monthly]

Recruiting PHASE3
May 2022 — Jun 2022 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Apr 2022 — May 2022 [monthly]

Not Yet Recruiting PHASE3
Mar 2022 — Apr 2022 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC

Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , ABB, Argentina , Adana, Turkey (Türkiye) , Akashi, Japan , Angers, France , Ankara, Turkey (Türkiye) , Antofagasta, Chile , Avignon, France , Bangkok, Thailand , Barcelona, Spain and 116 more locations